Ching W.  Jaw net worth and biography

Ching Jaw Biography and Net Worth

CFO of Cytokinetics

Ching joined us as Senior Vice President, Chief Financial Officer in June 2017.

Prior to joining Cytokinetics, Ching served as Chief Financial Officer of North America Pharmaceuticals at Sanofi from 2015 to 2017, and as the Chair of the North America Regional Finance Council. From 2012 to 2015, Ching was Chief Financial Officer for Ventana Medical Systems, a member of the Roche Group.

Previously, between 2001 and 2012, Ching held a wide variety of finance positions with Genentech, and then Roche, following their acquisition of Genentech, including two years as Chief Financial Officer of Roche in Taiwan and as Head of R&D Finance at Genentech.

A former Army Platoon Commander and Liaison Officer in the Taiwanese Army, Ching holds a Bachelor of Science degree in Naval Architecture from National Taiwan University, a Master of Science in Aerospace Engineering from the University of Michigan, and an M.B.A. in Finance and General Management from the University of Chicago Graduate School of Business.

In his spare time, Ching and his wife Connie enjoy outdoor activities such as hiking, biking, and skiing.

What is Ching W. Jaw's net worth?

The estimated net worth of Ching W. Jaw is at least $3.28 million as of April 4th, 2022. Mr. Jaw owns 67,109 shares of Cytokinetics stock worth more than $3,279,617 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Jaw may own. Learn More about Ching W. Jaw's net worth.

How do I contact Ching W. Jaw?

The corporate mailing address for Mr. Jaw and other Cytokinetics executives is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Cytokinetics can also be reached via phone at (650) 624-3000 and via email at [email protected]. Learn More on Ching W. Jaw's contact information.

Has Ching W. Jaw been buying or selling shares of Cytokinetics?

Ching W. Jaw has not been actively trading shares of Cytokinetics within the last three months. Most recently, Ching Jaw sold 15,000 shares of the business's stock in a transaction on Monday, April 4th. The shares were sold at an average price of $40.00, for a transaction totalling $600,000.00. Following the completion of the sale, the chief financial officer now directly owns 67,109 shares of the company's stock, valued at $2,684,360. Learn More on Ching W. Jaw's trading history.

Who are Cytokinetics' active insiders?

Cytokinetics' insider roster includes Muna Bhanji (Director), Robert Blum (President and Chief Executive Officer), Santo Costa (Director), David Cragg (Insider), L. Gage (Director), Robert Harrington (Director), John Henderson (Director), Ching Jaw (CFO), Edward Kaye (Director), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), Sandford Smith (Director), Wendall Wierenga (Director), and Robert Wong (CAO). Learn More on Cytokinetics' active insiders.

Are insiders buying or selling shares of Cytokinetics?

During the last year, insiders at the biopharmaceutical company sold shares 48 times. They sold a total of 454,133 shares worth more than $28,606,030.33. The most recent insider tranaction occured on December, 16th when Director Wendall Wierenga sold 742 shares worth more than $36,068.62. Insiders at Cytokinetics own 3.4% of the company. Learn More about insider trades at Cytokinetics.

Information on this page was last updated on 12/16/2024.

Ching W. Jaw Insider Trading History at Cytokinetics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/4/2022Sell15,000$40.00$600,000.0067,109View SEC Filing Icon  
3/9/2022Sell15,000$38.00$570,000.00View SEC Filing Icon  
10/19/2021Sell35,687$35.73$1,275,096.51View SEC Filing Icon  
10/5/2020Sell27,500$30.00$825,000.00View SEC Filing Icon  
8/21/2020Sell25,000$25.00$625,000.00View SEC Filing Icon  
See Full Table

Ching W. Jaw Buying and Selling Activity at Cytokinetics

This chart shows Ching Jaw's buying and selling at Cytokinetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cytokinetics Company Overview

Cytokinetics logo
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $48.87
Low: $46.85
High: $50.32

50 Day Range

MA: $52.09
Low: $46.36
High: $58.62

2 Week Range

Now: $48.87
Low: $36.24
High: $110.25

Volume

3,805,196 shs

Average Volume

1,988,956 shs

Market Capitalization

$5.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8